Acrivon Therapeutics Inc. Common Stock (ACRV) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Acrivon Therapeutics Inc....

NASDAQ: ACRV · Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Sep 25, 2025, 3:59 PM
1.55
0.65%
After-hours: Sep 25, 2025, 07:29 PM EDT

Acrivon Therapeutics Common Stock Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
1.01M 536K 1.09M 832K
Gross Profit
-1.01M -536K -1.09M -832K
Operating Income
-89.2M -67.24M -33.19M -16.48M
Interest Income
9.2M n/a n/a n/a
Pretax Income
-80.56M -60.39M -31.17M -16.24M
Net Income
-80.56M -60.39M -31.17M -16.24M
Selling & General & Admin
25.21M 21.21M 8.71M 2.47M
Research & Development
63.99M 45.49M 23.95M 13.72M
Other Expenses
-1.01M n/a n/a -541K
Operating Expenses
88.19M 66.7M 32.66M 15.64M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 134K n/a n/a
Cost & Expenses
89.2M 67.24M 33.19M 16.48M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
337.92M 22.08M 21.92M 20.86M
Shares Outstanding (Diluted)
337.92M 22.08M 21.92M 20.86M
EPS (Basic)
-0.24 -2.74 -1.42 -0.78
EPS (Diluted)
-0.24 -2.74 -1.42 -0.78
EBITDA
-79.55M -59.85M -30.07M -15.41M
EBIT
-80.56M -60.39M -31.17M -16.24M
Depreciation & Amortization
1.01M 536K 1.09M 832K